Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, Davis C, Eiber M, Hekimsoy T, Knoesen O, Kratochwil C, Lenzo NP, Mahapane J, Maserumule LC, Mdlophane AH, Mokoala KMG, Ndlovu H, Pant V, Rathke H, Reed J, Sen IB, Singh A, Sood A, Tauber R, Thakral P, Yadav MP, Morgenstern A. Sathekge MM, et al. Among authors: knoesen o. Lancet Oncol. 2024 Feb;25(2):175-183. doi: 10.1016/S1470-2045(23)00638-1. Epub 2024 Jan 11. Lancet Oncol. 2024. PMID: 38218192
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel FL, Van de Wiele C, Morgenstern A. Sathekge M, et al. Among authors: knoesen o. J Nucl Med. 2020 Jan;61(1):62-69. doi: 10.2967/jnumed.119.229229. Epub 2019 May 17. J Nucl Med. 2020. PMID: 31101746 Free article.
Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer.
Lawal IO, Morgenstern A, Vorster M, Knoesen O, Mahapane J, Hlongwa KN, Maserumule LC, Ndlovu H, Reed JD, Popoola GO, Mokoala KMG, Mdlophane A, Bruchertseifer F, Sathekge MM. Lawal IO, et al. Among authors: knoesen o. Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3581-3592. doi: 10.1007/s00259-022-05778-w. Epub 2022 Apr 6. Eur J Nucl Med Mol Imaging. 2022. PMID: 35384462 Review.
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C, Vorster M, Morgenstern A. Sathekge M, et al. Among authors: knoesen o. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138. doi: 10.1007/s00259-018-4167-0. Epub 2018 Sep 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 30232539 Free PMC article.
Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617.
Sathekge MM, Bruchertseifer F, Lawal IO, Vorster M, Knoesen O, Lengana T, Boshomane TG, Mokoala KK, Morgenstern A. Sathekge MM, et al. Among authors: knoesen o. Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1756-1757. doi: 10.1007/s00259-019-04354-z. Epub 2019 May 21. Eur J Nucl Med Mol Imaging. 2019. PMID: 31115638 No abstract available.
mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Mdlophane A, Maes A, Mokoala K, Mathabe K, Van C, Wiele D, Morgenstern A. Sathekge M, et al. Among authors: knoesen o. J Nucl Med. 2022 Oct;63(10):1496-1502. doi: 10.2967/jnumed.121.263618. Epub 2022 Feb 17. J Nucl Med. 2022. PMID: 35177427 Free PMC article.
11 results